Phio Pharmaceuticals Corp. Profile Avatar - Palmy Investing

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates…

Biotechnology
US, Marlborough [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of PHIO's Analysis
CIK: 1533040 CUSIP: 71880W303 ISIN: US71880W4024 LEI: - UEI: -
Secondary Listings
PHIO has no secondary listings inside our databases.